Biotechnology
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Departmen...
2025-05-16 09:00
2678
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, tod...
2025-05-15 21:13
2366
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 11:30
2010
Novonesis Co-Hosts Partnering Day 2025 in Singapore to Advance Biosolutions for a Sustainable Future
SINGAPORE, May 13, 2025 /PRNewswire/ -- Novonesis
2025-05-14 13:17
2367
Avance Clinical Honored with Frost & Sullivan's 2025 Global Customer Value Leadership Award for Transformative Biotech CRO Services
This award recognizes Avance Clinical's strategic innovation, operational agility, and unwavering commitment to client success in early-phase clinical trials. SAN ANTONIO, May 14, 2025 /PRNewswire/ -- Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Lead...
2025-05-14 13:00
1448
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
* Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo. SING...
2025-05-14 10:30
2160
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
* Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology com...
2025-05-13 17:00
2039
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the 2025 ESMO G...
2025-05-13 11:38
2055
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希® ), the first domestically approved antibody-drug conjugate (ADC...
2025-05-12 16:29
4604
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof.Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research[1], authored b...
2025-05-12 15:44
2601
Asia's First Real-World ctDNA-MRD Study Strengthens Evidence for Cost-Effective Cancer Monitoring
A landmark study recently published in March 2025 by JCO Oncology Advances,
demonstrates the potential ofK-TRACKTM
2025-05-09 14:01
2650
DNV recognized as a Notified Body for Certification under In Vitro Diagnostic Regulation (IVDR)
OSLO, Norway, May 8, 2025 /PRNewswire/ -- DNV, the independent assurance and risk management provider, has been recognized by the European Commission as a notified body for the certification of devices under the European Union's In Vitro Diagnostic Regulation (IVDR). The designation increases cap...
2025-05-08 22:38
2266
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous HBV-specific...
2025-05-08 09:00
2338
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
* End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179naïve participants, strengthening the case for a novel enrichmen...
2025-05-08 08:10
2577
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published inThyroid, the official journal of the ...
2025-05-08 05:00
2230
Minaris Advanced Therapies launches as the leading global partner dedicated to cell therapy development, manufacturing, and testing
New company unveiled at the annual ISCT conference in New Orleans combines two tenured and innovative CDMOs with a testing powerhouse PHILADELPHIA, May 7, 2025 /PRNewswire/ -- Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S...
2025-05-07 20:12
2215
Benchling and Moderna Collaborate on AI-Driven Research
SAN FRANCISCO and BOSTON, May 7, 2025 /PRNewswire/ -- Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration withModerna. What began with Benchling supporting Moderna's technical development teams — such as analytical development, technical operation...
2025-05-07 19:00
1807
The world's first: Grand Pharma's global innovative product STC3141 successfully reached the clinical endpoint in the Phase II clinical study in China
* The results showed that the SOFA scores of the drug treatment groups on the 7th day were significantly lower than those of the baseline, especially in the high-dose group, where the decrease was significantly greater than that in the placebo group, of which the difference was statistically si...
2025-05-07 14:19
3688
Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World
SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that sequences while you sleep, today announced the opening of its tenth global sequencing lab, located inSingapore's vibrant biomedical hub. The new site dramatically shortens turnaround times for ...
2025-05-06 23:56
2491
Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with Plans for Commercialization in the U.S. MT PLEASANT, S...
2025-05-06 22:12
2770
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4847
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
4093
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3950
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3868
